Evaluation of Wnt5a and LRP5 Levels in Serum and Saliva Samples and the Relationship Between Clinical Periodontal Parameters
NCT ID: NCT06933784
Last Updated: 2025-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2024-04-01
2025-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Method: Saliva and serum samples were collected from 20 systemically healthy patients with stage III periodontitis and 20 periodontally healthy controls. Wnt5a and LRP5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL) were recorded.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Potential Effects of LRP5 and Tph1 in the Pathogenesis of Periodontal Disease Individuals With Stage III Grade B Periodontitis
NCT06933797
Netrin 1 and Its Receptor Unc5b as Markers of Periodontal Disease
NCT03919006
EVALUATION OF SALIVA AND SERUM HEME OXYGENASE, ARYLESTERASE AND NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 LEVELS IN PATIENTS WITH STAGE III PERIODONTITIS
NCT06986044
Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin (OPG) and RANKL in Health, Disease and After Treatment
NCT02390479
Estimation of Pentrexin-3 Levels in GCF and Saliva of Patients With Periodontal Disease
NCT03128502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage III periodontitis Grade B
Individuals exhibiting pocket depths of \>3 mm in at least two non-adjacent teeth, radiographic evidence of alveolar bone loss extending to the middle or apical third of the root, and tooth loss of ≤4 due to periodontitis were classified as having Stage III periodontitis. The additional criterion for Grade B classification was defined as a % bone loss/age ratio of 0.25-1.
No interventions assigned to this group
Periodontally healthy
Individuals with no signs of alveolar bone loss and an overall oral bleeding score \<10% were categorized as periodontally healthy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 16 permanent teeth except 3rd molars,
* Individuals who do not use orthodontic appliances,
* Individuals who are not pregnant or lactating,
* Individuals without any systemic disease that may affect periodontal health,
* Systemically healthy individuals,
* Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
* Individuals who have not received periodontal treatment in the last 1 year
Exclusion Criteria
* Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
* Individuals who have undergone periodontal treatment in the last 1 year,
* Individuals with psychiatric illness,
* Individuals with any oral infection,
* Individuals with \<16 teeth, excluding molars,
* Individuals with alcohol dependence,
* Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
* Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Scientific and Technological Research Council of Turkey
OTHER
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zulal Deniz Guner
Sub-Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara University, Faculty of Dentistry
Ankara, Yenimahalle, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Guney Z, Kurgan S, Onder C, Tayman MA, Gunhan O, Kantarci A, Serdar MA, Gunhan M. Wnt signaling in periodontitis. Clin Oral Investig. 2023 Nov;27(11):6801-6812. doi: 10.1007/s00784-023-05294-7. Epub 2023 Oct 10.
Zhao Y, Zhang C, Huang Y, Yu Y, Li R, Li M, Liu N, Liu P, Qiao J. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-kappaB signaling in the granulosa cells of PCOS patients. J Clin Endocrinol Metab. 2015 Jan;100(1):201-11. doi: 10.1210/jc.2014-2419.
Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009 Feb;24(2):171-8. doi: 10.1359/jbmr.081235.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1919B012324587
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
36290600/02/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.